Aberdeen Group plc Trims Holdings in Arbutus Biopharma Corporation $ABUS

Aberdeen Group plc lessened its holdings in Arbutus Biopharma Corporation (NASDAQ:ABUS) by 18.6% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 799,979 shares of the biopharmaceutical company’s stock after selling 182,548 shares during the period. Aberdeen Group plc’s holdings in Arbutus Biopharma were worth $3,632,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Oxford Asset Management LLP purchased a new stake in shares of Arbutus Biopharma in the 2nd quarter valued at $38,000. Daiwa Securities Group Inc. lifted its position in Arbutus Biopharma by 3,911.1% during the second quarter. Daiwa Securities Group Inc. now owns 15,844 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 15,449 shares during the period. Prudential Financial Inc. boosted its holdings in Arbutus Biopharma by 71.5% in the second quarter. Prudential Financial Inc. now owns 18,255 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 7,610 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in Arbutus Biopharma during the 2nd quarter worth about $61,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Arbutus Biopharma by 220.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 20,760 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 14,275 shares during the last quarter. 43.79% of the stock is currently owned by institutional investors and hedge funds.

Arbutus Biopharma Price Performance

Shares of ABUS stock opened at $4.27 on Friday. Arbutus Biopharma Corporation has a 1-year low of $2.70 and a 1-year high of $5.10. The company has a market cap of $821.21 million, a price-to-earnings ratio of -18.57 and a beta of 0.71. The stock has a 50 day simple moving average of $4.38 and a 200-day simple moving average of $4.28.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Arbutus Biopharma in a research note on Wednesday, January 21st. Chardan Capital reaffirmed a “buy” rating and set a $5.00 price objective on shares of Arbutus Biopharma in a research note on Friday, November 14th. Finally, Wall Street Zen cut shares of Arbutus Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $5.00.

Arbutus Biopharma Profile

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core.

In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics.